Fundraising Includes Strategic Investment by Bristol Myers Squibb Coupled with Support from Existing Investors EvolveImmune Initiates Chemistry, Manufacturing, and Control (CMC) Activities for Lead...
Immunotherapy biotech EvolveImmune Therapeutics raised $37 million in a financing round, backed by big names like Pfizer and its newest investor, Bristol Myers Squibb.
EvolveImmune to Highlight New Data on Precision Medicine Potential of Evolve Platform and Lead Development Programs in Presentations at SITC 2023
BRANFORD, Conn., June 14, 2023 (GLOBE NEWSWIRE) -- EvolveImmune Therapeutics, an immuno-oncology company developing first-in-category, multifunctional biotherapeutics to overcome cancer-driven...
EvolveImmune Therapeutics Presents New Preclinical Data Demonstrating Improved Anti-Tumor Potential of Novel Costimulatory T Cell Engager Platform at Festival of Biologics Immunotherapy World Congress
BRANFORD, Conn., Nov. 10, 2022 (GLOBE NEWSWIRE) -- EvolveImmune Therapeutics, an immuno-oncology company developing first-in-category, multifunctional biotherapeutics to overcome cancer-driven immunodeficiency, today announced that new preclinical data highlighting EVOLVE™, the company’s novel costimulatory T cell engager platform, were presented at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC). The results were featured in a poster presentation (#1060) entitled, “EVOLVE: a Novel Costimulatory T Cell Engager Platform Engineered for the Treatment of Immune Suppressive Tumors,” at the conference, which is being held November 8-12, 2022, in Boston.